These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38754208)

  • 1. Evaluating pharmacological treatments for excessive daytime sleepiness in obstructive sleep apnea: A comprehensive network meta-analysis and systematic review.
    Neshat SS; Heidari A; Henriquez-Beltran M; Patel K; Colaco B; Arunthari V; Lee Mateus AY; Cheung J; Labarca G
    Sleep Med Rev; 2024 Aug; 76():101934. PubMed ID: 38754208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis.
    Pitre T; Mah J; Roberts S; Desai K; Gu Y; Ryan C; Busse JW; Zeraatkar D
    Ann Intern Med; 2023 May; 176(5):676-684. PubMed ID: 37155992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
    Ronnebaum S; Bron M; Patel D; Menno D; Bujanover S; Kratochvil D; Lucas E; Stepnowsky C
    J Clin Sleep Med; 2021 Dec; 17(12):2543-2555. PubMed ID: 34402784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Persistent Excessive Daytime Sleepiness in OSA.
    Javaheri S; Javaheri S
    Chest; 2020 Aug; 158(2):776-786. PubMed ID: 32147246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.
    Subedi R; Singh R; Thakur RK; K C B; Jha D; Ray BK
    Sleep Med; 2020 Nov; 75():510-521. PubMed ID: 33032062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Modafinil and Armodafinil in Patients With Obstructive Sleep Apnea: A Meta-analysis of Randomized Controlled Trials.
    Kuan YC; Wu D; Huang KW; Chi NF; Hu CJ; Chung CC; Tam KW; Huang YH
    Clin Ther; 2016 Apr; 38(4):874-88. PubMed ID: 26923035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.
    Schweitzer PK; Mayer G; Rosenberg R; Malhotra A; Zammit GK; Gotfried M; Chandler P; Baladi M; Strohl KP
    Chest; 2021 Jul; 160(1):307-318. PubMed ID: 33631141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials.
    Wang J; Yang S; Li X; Wang T; Xu Z; Xu X; Gao H; Chen G
    Sleep Med; 2021 Mar; 79():40-47. PubMed ID: 33472129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study.
    Inoue Y; Takasaki Y; Yamashiro Y
    J Clin Sleep Med; 2013 Aug; 9(8):751-7. PubMed ID: 23946704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: A meta-analysis from randomized controlled trials.
    Wang J; Li X; Yang S; Wang T; Xu Z; Xu J; Gao H; Chen G
    Pharmacol Res; 2021 May; 167():105522. PubMed ID: 33667687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study.
    Herring WJ; Liu K; Hutzelmann J; Snavely D; Snyder E; Ceesay P; Lines C; Michelson D; Roth T
    Sleep Med; 2013 Oct; 14(10):955-63. PubMed ID: 23920422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excessive daytime sleepiness in obstructive sleep apnea: Indirect treatment comparison of wake-promoting agents in patients adherent/nonadherent to primary OSA therapy.
    Wang Y; Zhang W; Ye H; Xiao Y
    Sleep Med Rev; 2024 Dec; 78():101997. PubMed ID: 39243682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysis.
    Pépin JL; Lehert P; Ben Messaoud R; Joyeux-Faure M; Caussé C; Asin J; Barbé F; Bonsignore MR; Randerath W; Verbraecken J; Craig S; Dauvilliers Y
    EClinicalMedicine; 2024 Oct; 76():102843. PubMed ID: 39346006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.
    Krystal AD; Benca RM; Rosenberg R; Schweitzer PK; Malhotra A; Babson K; Lee L; Bujanover S; Strohl KP
    J Psychiatr Res; 2022 Nov; 155():202-210. PubMed ID: 36070638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Findings of the Maintenance of Wakefulness Test and its relationship with response to modafinil therapy for residual excessive daytime sleepiness in obstructive sleep apnea patients adequately treated with nasal continuous positive airway pressure.
    Inoue Y; Miki M; Tabata T
    Sleep Med; 2016; 27-28():45-48. PubMed ID: 27938918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Wakefulness-Promoting Agents on Sleepiness in Patients with Sleep Apnea Treated with CPAP: A Meta-Analysis.
    Sukhal S; Khalid M; Tulaimat A
    J Clin Sleep Med; 2015 Oct; 11(10):1179-86. PubMed ID: 25979103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study.
    Strollo PJ; Hedner J; Collop N; Lorch DG; Chen D; Carter LP; Lu Y; Lee L; Black J; Pépin JL; Redline S;
    Chest; 2019 Feb; 155(2):364-374. PubMed ID: 30471270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
    Krief S; Berrebi-Bertrand I; Nagmar I; Giret M; Belliard S; Perrin D; Uguen M; Robert P; Lecomte JM; Schwartz JC; Finance O; Ligneau X
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00855. PubMed ID: 34423920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial.
    Dauvilliers Y; Verbraecken J; Partinen M; Hedner J; Saaresranta T; Georgiev O; Tiholov R; Lecomte I; Tamisier R; Lévy P; Scart-Gres C; Lecomte JM; Schwartz JC; Pépin JL;
    Am J Respir Crit Care Med; 2020 May; 201(9):1135-1145. PubMed ID: 31917607
    [No Abstract]   [Full Text] [Related]  

  • 20. Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial.
    Chapman JL; Kempler L; Chang CL; Williams SC; Sivam S; Wong KK; Yee BJ; Grunstein RR; Marshall NS
    Thorax; 2014 Mar; 69(3):274-9. PubMed ID: 24287166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.